Patent intelligence · US
US 12208123
Compositions and methods for the treatment of skin conditions
Compositions and methods for the treatment of skin conditions
Patent details — US 12208123
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 28, 2025
- Expiration
- Jan 23, 2045
- Applicant
- DERMATA THERAPEUTICS, INC.
- Claims
- 44
- CPC classes
- A61K, A61K31/327, A61K35/655, A61K47/02
Quick answer
US 12208123 (Compositions and methods for the treatment of skin conditions) is held by DERMATA THERAPEUTICS, INC.. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- DERMATA THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 44
- CPC classes
- A61K, A61K31/327, A61K35/655, A61K47/02, A61K9/0014, A61P
More from DERMATA THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 6759396
Compositions based on a synergistic mixture of at least one VDR ligand and a retinoid
expired -
US 6593359
Use of a RAR-&ggr;-specific agonist ligand for increasing the rate of apoptosis
expired -
US 6515021
Bicyclic aromatic compounds
expired -
US 6506796
Use of a RAR-&ggr;-specific agonist ligand for increasing the rate of apoptosis
expired -
US 6368608
Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof
expired -
US 6326510
Bi-aromatic compounds, compositions containing them and uses
expired -
US 6313162
Propynyl or dienyl biaromatic compounds
expired
Frequently asked questions
What is US patent 12208123?
US 12208123 (Compositions and methods for the treatment of skin conditions) is held by DERMATA THERAPEUTICS, INC.. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12208123?
DERMATA THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 30 pharmaceutical patents for this assignee.
When does US 12208123 expire?
Our index shows an expiration date of Jan 23, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.